Tandem Diabetes Tackling Challenges and Innovating Solutions in Insulin Delivery, | CSIMarket News

Tandem Diabetes Tackling Challenges and Innovating Solutions in Insulin Delivery,

Published | Modified
CSIMarket Newsroom | CSIMarket.com
Illustrative image

San Diego’ Tandem Diabetes Care, Inc. has announced the release of an updated version of its Apple iOS t:connect mobile app, designed specifically for users of the t:slim X2 insulin pump. Scheduled to be available on August 20, 2024, the app update, version 2.8.2, aims to correct battery depletion issues that were highlighted in a nationwide recall issued in March 2024.

Users of the t:slim X2 insulin pump have reported experiencing unexpected battery drain, which can lead to the device shutting down before the expected time. This technical issue has persisted for some San Diego’ "https://csimarket.com/stocks/at_glance.php?code=TNDM">TNDM">customers even after the prior update to version 2.7.1. The upcoming version 2.8.2 is anticipated to resolve these concerns and enhance the reliability of the insulin delivery system.

Additionally, Tandem Diabetes Care has made strides in expanding the functionality of its insulin pumps. The company recently confirmed that its Tandem Mobi insulin pump, featuring Control-IQ technology, is now fully compatible with the Dexcom G7 and G6 Continuous Glucose Monitoring (CGM) Systems. This compatibility means that users can now benefit from an integrated system that combines automated insulin delivery with advanced glucose monitoring, improving diabetes management.

The Tandem Mobi, recognized as the smallest and most durable automated insulin delivery system currently available, was launched in the United States earlier this year. This strategic move positions Tandem as a leader in the diabetes technology market, offering patients effective solutions for managing their health.

These developments mark a critical response to the challenges faced by users in managing their diabetes and reinforce Tandem Diabetes Care’s commitment to improving patient outcomes through technological enhancements.

Sources for this article: Based on Tandem Diabetes Care Inc ’s official statement and CSIMarket.com’s Assessment of Competitive Landscape
For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .
Tags:
#BusinessUpdate, #NasdaqTandemDiabetesCareTandemDiabetesCarePr, #competitors, #IncHaveTandemDiabetesCareIncThursdayStreet, #RevenuesConcernedAfter, #Get, #StockStock, #TNDM, #Tandem Diabetes Care Inc, #Medical Equipment & Supplies
Share this article:
Link copied to clipboard.

Comments

Comments are available to active subscribers. Subscribe or Log in.
Get the full CSIMarket dataset: Subscribe API License